Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate

• Published in: Clinical cancer research 2006-03, Vol.12 (6), p.1743-1749
• Main Authors: Wardelmann, Eva, Merkelbach-Bruse, Sabine, Pauls, Katharina, Thomas, Nadja, Schildhaus, Hans-Ulrich, Heinicke, Thomas, Speidel, Nicola, Pietsch, Torsten, Buettner, Reinhard, Pink, Daniel, Reichardt, Peter, Hohenberger, Peter
• Format: Article
• Language: English
• Subjects: Adult; Aged; Amino Acid Sequence; Base Sequence; Benzamides; DNA Mutational Analysis; Female; Gastrointestinal cancers: other; Gastrointestinal Stromal Tumors - drug therapy; Gastrointestinal Stromal Tumors - genetics; Gastrointestinal Stromal Tumors - pathology; Genetic instability: multistep progression; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Oncology; Molecular Sequence Data; Mutagenesis; Mutation - drug effects; Piperazines - therapeutic use; Protein Kinase Inhibitors - therapeutic use; Proto-Oncogene Proteins c-kit - genetics; Pyrimidines - therapeutic use; Sarcoma/soft-tissue malignancies; Sequence Homology, Amino Acid
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-05-1211

Gastrointestinal stromal tumors (GIST) are characterized by a strong KIT receptor activation most often resulting from KIT mutations. In a smaller subgroup of tumors without KIT mutations, analogous activating mutations are found in the platelet-derived growth factor receptor α ( PDGFRα ) gene. Both PDGFRα and KIT receptors are targets of the tyrosine kinase inhibitor imatinib (Glivec) which has improved the treatment of advanced GISTs significantly. However, a subgroup of tumors show a secondary progress under therapy with imatinib after initial response. One possible mechanism of secondary resistance is the development of newly acquired KIT mutations. In the present study, we evaluated the frequency of such secondary KIT mutations in a series of GIST patients in which tumor tissue was resected under treatment. We examined one to seven different tumor areas in 32 cases (total of 104 samples) and found up to four newly acquired KIT mutations in 14 patients (43.8%). These were always located in exons encoding the first or second tyrosine kinase domain (exon 13, 14, or 17). Mutations were found only in a subset of samples analyzed from each case whereas others retained the wild-type sequence in the same region. There was never more than one new mutation in the same sample. Consistent with a secondary clonal evolution, the primary mutation was always detectable in all samples from each tumor. According to our results, the identification of newly acquired KIT mutations in addition to the primary mutation is dependent on the number of tissue samples analyzed and has high implications for further therapeutic strategies.